Related Experiment Videos
[Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors]
1Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
Abstract:
Based on recent progress in cancer biology, numerous molecules that contribute to proliferation, invasion, and metastasis of cancer cells have been identified. The epidermal growth factor receptor (EGFR), a member of cell membrane receptors, is overexpressed by many tumors, and EGFR overexpression correlates with poor prognosis and disease progression. The EGFR is an attractive target for novel anticancer therapy. ZD1839 and OSI-774, highly specific EGFR tyrosine kinase inhibitors, have shown promising antitumor activity against cisplatin-resistant non-small cell lung cancer in phase I and phase II trials. IMC-C225, a monoclonal antibody against EGFR, has achieved significant disease control in head and neck cancer and colorectal cancer in combination with anticancer agents. These agents are under evaluation in phase III trials. In conclusion, it is expected that EGFR-directed therapies will soon be established as an effective novel treatment for many cancer patients.
Insights
Epidermal growth factor receptor (EGFR) is a key target in cancer. EGFR-targeted therapies, including tyrosine kinase inhibitors and monoclonal antibodies, show promise for treating various cancers and are advancing to phase III trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) is frequently overexpressed in tumors, correlating with poor prognosis and disease progression.
- EGFR plays a crucial role in cancer cell proliferation, invasion, and metastasis.
- Targeting EGFR presents a promising strategy for novel anticancer therapies.
Purpose of the Study:
- To review recent advancements in EGFR-directed cancer therapies.
- To highlight the efficacy of specific EGFR inhibitors and antibodies in clinical trials.
- To discuss the potential of EGFR-targeted treatments for various cancers.
Main Methods:
- Review of recent progress in cancer biology and EGFR research.
- Analysis of clinical trial data (Phase I, II, and III) for EGFR-targeted agents.
- Evaluation of specific EGFR inhibitors (ZD1839, OSI-774) and a monoclonal antibody (IMC-C225).
Main Results:
- ZD1839 and OSI-774 demonstrated antitumor activity in cisplatin-resistant non-small cell lung cancer.
- IMC-C225 achieved significant disease control in head and neck and colorectal cancers when combined with other agents.
- These agents are progressing to Phase III trials, indicating promising therapeutic potential.
Conclusions:
- EGFR-directed therapies are emerging as effective novel treatments for cancer.
- Targeting EGFR holds significant potential for improving outcomes in various cancer types.
- Further clinical evaluation in Phase III trials is expected to establish EGFR-targeted treatments as standard care.